Wire · opportunities
Kerendia Earns FDA Approval for CKD in Type 1 Diabetes
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 19 September 2026 · Fusion42 review
The FDA approved Kerendia (finerenone) to reduce urinary albumin-to-creatinine ratio (UACR) in adults with chronic kidney disease (CKD) linked to type 1 diabetes, a treatment expected to slow kidney function decline and prevent end-stage kidney disease.
This Wire brief sits within Fusion42's coverage of Biotech, and 5 sources have reported it between 17 Sep 2026 and 22 Sep 2026.
◆ ◆ The Wire takeaway
You now have a newly FDA-approved drug option to address chronic kidney disease in type 1 diabetes patients, disrupting a market long without progress. This opens a door for biotech ventures specialising in kidney disease treatments to accelerate development or partnerships.
◆ Coverage
5 sources · first reported 17 Sep 2026 · latest 22 Sep 2026
◆ Related on Wire
◆ Topics